{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:37:28Z","timestamp":1794591448041,"version":"4.9.1"},"reference-count":36,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>While sodium\u2013glucose cotransporter inhibitor (SGLTi) therapy has been evaluated in type 1 diabetes (T1D) trials, patient reactions to benefits and risks are unknown. Using established methodology, we evaluated patient preferences for different adjunct-to-insulin therapy options in T1D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>An online survey, completed by 701 respondents with T1D (231 U.S., 242 Canada, and 228 Germany), used conjoint analysis to present six hypothetical, masked, pairwise drug profile choices composed of different benefit-risk attributes and effect ranges. Data used in analyses were derived from actual phase 3 trials of a low-dose SGLTi (comparable to oral empagliflozin 2.5 mg q.d.), a high-dose SGLTi (comparable to oral sotagliflozin 400 mg q.d.), and an available adjunct-to-insulin therapy (comparable to subcutaneous pramlintide 60 \u03bcg t.i.d.).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Conjoint analysis identified diabetic ketoacidosis risk as most important to patients (23% relative score; z test, P &amp;lt; 0.05); ranked second were HbA1c reduction (14%), risk of severe hypoglycemia (13%), oral versus injectable treatment (12%), and risk of genital infection (12%). Next was risk of nausea (11%), followed by weight reduction (8%) and the risk of diarrhea (7%). A low-dose SGLTi drug profile was identified by conjoint analysis as the top patient preference (83% of participants; z test, P &amp;lt; 0.05) versus high-dose SGLTi (8%) or pramlintide (9%). Separate from conjoint analysis, when respondents were asked to choose their preferred adjunct-to-insulin therapy (masked to drug name\/dose), 69%, 17%, 6%, and 9% of respondents chose low-dose SGLTi, high-dose SGLTi, pramlintide, and insulin therapy alone, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Low-dose SGLTi profile was the favored adjunct-to-insulin therapy by persons with T1D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc19-0548","type":"journal-article","created":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T18:05:11Z","timestamp":1560017111000},"page":"1716-1723","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":24,"title":["Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes"],"prefix":"10.2337","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-0046","authenticated-orcid":false,"given":"Bruce A.","family":"Perkins","sequence":"first","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Division of Endocrinology and Metabolism, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes Research Center at Medical City, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-8110","authenticated-orcid":false,"given":"Jay S.","family":"Skyler","sequence":"additional","affiliation":[{"name":"Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9675-3001","authenticated-orcid":false,"given":"Lori M.","family":"Laffel","sequence":"additional","affiliation":[{"name":"Joslin Diabetes Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David Z.","family":"Cherney","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6099-2406","authenticated-orcid":false,"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Endocrinology, University Hospital Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christianne","family":"Pang","sequence":"additional","affiliation":[{"name":"dQ&A, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wood","sequence":"additional","affiliation":[{"name":"dQ&A, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ona","family":"Kinduryte","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothis T.","family":"George","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Marquard","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Soleymanlou","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim (Canada) Ltd.\/Lt\u00e9e, Burlington, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,7,11]]},"reference":[{"key":"2022031300570076200_B1","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300570076200_B2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/dia.2018.0384","article-title":"State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018","volume":"21","author":"Foster","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"2022031300570076200_B3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2337\/dc15-0078","article-title":"Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry","volume":"38","author":"Miller","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031300570076200_B4","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"key":"2022031300570076200_B5","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.2337\/dc17-0403","article-title":"Use of adjuvant pharmacotherapy in type 1 diabetes: international comparison of 49,996 individuals in the Prospective Diabetes Follow-up and T1D Exchange registries","volume":"40","author":"Lyons","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031300570076200_B6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031300570076200_B7","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031300570076200_B8","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300570076200_B9","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300570076200_B10","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 Study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300570076200_B11","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300570076200_B12","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300570076200_B13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031300570076200_B14","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031300570076200_B15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031300570076200_B16","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1056\/NEJMe1711296","article-title":"Adjunctive treatments for type 1 diabetes","volume":"377","author":"Nathan","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031300570076200_B17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S2213-8587(17)30315-7","article-title":"SGLT2 inhibitors in type 1 diabetes: knocked down, but up again","volume":"5","author":"Petrie","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031300570076200_B18","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s00125-018-4671-6","article-title":"SGLT inhibitor adjunct therapy in type 1 diabetes","volume":"61","author":"McCrimmon","year":"2018","journal-title":"Diabetologia"},{"key":"2022031300570076200_B19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"2022031300570076200_B20","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.2337\/db13-1093","article-title":"Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Study at 30 years: advances and contributions","volume":"62","author":"Nathan","year":"2013","journal-title":"Diabetes"},{"key":"2022031300570076200_B21","doi-asserted-by":"crossref","first-page":"44128","DOI":"10.1038\/srep44128","article-title":"The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"2022031300570076200_B22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.diabres.2018.01.004","article-title":"Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: a systematic review and meta-analysis","volume":"137","author":"El Masri","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031300570076200_B23","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/dom.13260","article-title":"Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Yamada","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022031300570076200_B24","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00228-014-1730-x","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis","volume":"70","author":"Yang","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2022031300570076200_B25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"2022031300570076200_B26","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2022031300570076200_B27","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031300570076200_B28","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jc.2013-1589","article-title":"Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry","volume":"98","author":"Weinstock","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300570076200_B29","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/dia.2018.0246","article-title":"Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol","volume":"20","author":"Garg","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"2022031300570076200_B30"},{"key":"2022031300570076200_B31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.15585\/mmwr.mm6712a3","article-title":"Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality - United States, 2000-2014","volume":"67","author":"Benoit","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022031300570076200_B32","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1136\/bmj.320.7248.1530","article-title":"Using conjoint analysis to elicit preferences for health care","volume":"320","author":"Ryan","year":"2000","journal-title":"BMJ"},{"key":"2022031300570076200_B33","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1186\/s12885-016-2975-9","article-title":"Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany","volume":"16","author":"Hofheinz","year":"2016","journal-title":"BMC Cancer"},{"key":"2022031300570076200_B34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jval.2016.04.008","article-title":"Patient preferences in regulatory benefit-risk assessments: a US perspective","volume":"19","author":"Johnson","year":"2016","journal-title":"Value Health"},{"key":"2022031300570076200_B35","first-page":"84","article-title":"Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis","volume":"9","author":"Louder","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2022031300570076200_B36","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s13300-017-0326-8","article-title":"Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey","volume":"8","author":"Mansfield","year":"2017","journal-title":"Diabetes Ther"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc19-0548","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/9\/1716\/529464\/dc190548.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/9\/1716\/529464\/dc190548.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:29:28Z","timestamp":1647127768000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/42\/9\/1716\/36339\/Exploring-Patient-Preferences-for-Adjunct-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,7,11]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc19-0548","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,11]]}}}